Abivax SA (ABVX)
NASDAQ: ABVX · IEX Real-Time Price · USD
13.82
-0.13 (-0.93%)
May 14, 2024, 2:53 PM EDT - Market open
Company Description
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases.
The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.
ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
Abivax SA
| Country | United States |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 61 |
| CEO | Marc M. P. de Garidel M.B.A. |
Contact Details
Address: 7 Bd Haussmann Paris, I0 75009 France | |
| Phone | 01 53 83 09 63 |
| Website | abivax.com |
Stock Details
| Ticker Symbol | ABVX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $11.60 |
| CIK Code | 0001956827 |
| ISIN Number | US00370M1036 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Marc M. P. de Garidel M.B.A. | Chief Executive Officer and Interim Chair of Board |
| Dr. Philippe Pouletty M.D., Ph.D. | Founder and Director |
| Didier Blondel | EVice President, Chief Financial Officer and Board Secretary |
| Didier Scherrer Ph.D. | Chief Scientific Officer |
| Patrick Malloy | Senior Vice President of Investor Relations |
| Ida Hatoum | Chief People Officer |
| Pierre Courteille M.B.A. | Chief Business Officer |
| Jérôme Denis | Executive Vice President of Process Development and Manufacturing |
| Sheldon Sloan M.D. | Chief Medical Officer |
| Michael Ferguson B.S., M.B.A. | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 7, 2024 | 6-K | Report of foreign issuer |
| Apr 19, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Apr 5, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Apr 2, 2024 | 6-K | Report of foreign issuer |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 2, 2024 | 6-K | Report of foreign issuer |
| Jan 22, 2024 | 6-K | Report of foreign issuer |
| Nov 22, 2023 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 30, 2023 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 30, 2023 | SC 13D | General statement of acquisition of beneficial ownership |